Iovance Biotherapeutics Inc (IOVA) ticks all the boxes for top investors with its surprise performance of -6.01% last month.

On Monday Iovance Biotherapeutics Inc (NASDAQ: IOVA) was 1.78% up from the session before settling in for the closing price of $1.69. A 52-week range for IOVA has been $1.64 – $12.51.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 4.17% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 12.10%. With a float of $271.49 million, this company’s outstanding shares have now reached $333.93 million.

In an organization with 838 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 19.2%, operating margin of -187.5%, and the pretax margin is -178.03%.

Iovance Biotherapeutics Inc (IOVA) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Iovance Biotherapeutics Inc stocks. The insider ownership of Iovance Biotherapeutics Inc is 18.70%, while institutional ownership is 64.00%. The most recent insider transaction that took place on Jun 05 ’25, was worth 55,200. In this transaction Chief Commercial Officer of this company bought 30,000 shares at a rate of $1.84, taking the stock ownership to the 30,000 shares. Before that another transaction happened on May 23 ’25, when Company’s Chief Regulatory Officer bought 5,600 for $1.74, making the entire transaction worth $9,743. This insider now owns 206,852 shares in total.

Iovance Biotherapeutics Inc (IOVA) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 12.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.97% during the next five years compared to 4.17% growth over the previous five years of trading.

Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators

You can see what Iovance Biotherapeutics Inc (IOVA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.70.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.77 in one year’s time.

Technical Analysis of Iovance Biotherapeutics Inc (IOVA)

Let’s dig in a bit further. During the last 5-days, its volume was 11.57 million. That was inferior than the volume of 11.68 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.73%.

During the past 100 days, Iovance Biotherapeutics Inc’s (IOVA) raw stochastic average was set at 1.80%, which indicates a significant decrease from 7.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.96% in the past 14 days, which was lower than the 125.38% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $2.3200, while its 200-day Moving Average is $5.9672. However, in the short run, Iovance Biotherapeutics Inc’s stock first resistance to watch stands at $1.7600. Second resistance stands at $1.8000. The third major resistance level sits at $1.8300. If the price goes on to break the first support level at $1.6900, it is likely to go to the next support level at $1.6600. The third support level lies at $1.6200 if the price breaches the second support level.

Iovance Biotherapeutics Inc (NASDAQ: IOVA) Key Stats

There are 333,934K outstanding shares of the company, which has a market capitalization of 574.37 million. As of now, sales total 164,070 K while income totals -372,180 K. Its latest quarter income was 49,320 K while its last quarter net income were -116,160 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.